Scinai Immunotherapeutics Congratulates its Co-Lead Scientific Research Collaborator Dirk Görlich on Louis-Jeantet Prize

January 25, 2024

https://www.prnewswire.com/news-releases/scinai-immunotherapeutics-congratulates-its-co-lead-scientific-research-collaborator-dirk-gorlich-on-louis-jeantet-prize-302044842.html

JERUSALEM, Jan. 25, 2024 /PRNewswire/ — Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on development of inflammation and immunology (I&I) biological products, congratulates the Company’s co-lead scientific research collaborator Professor Dr. Dirk Görlich on being awarded the 2024 Louis-Jeantet Prize. Established in 1986, the prestigious CHF 500,000 (US$ 576,000) prize is awarded annually to European-based researchers in recognition of groundbreaking work in the field of biomedicine.

Read more at prnewswire.com

Related news for (SCNI)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.